Insulin Glargine YFGN and Lantus Have the Same Strength
Yes, insulin glargine YFGN has the same strength as Lantus, both containing insulin glargine at the same concentration (100 units/mL).
Understanding Insulin Glargine Products
Insulin glargine is a long-acting basal insulin analog that provides relatively constant, peakless glucose-lowering activity for approximately 24 hours. According to the American Diabetes Association (ADA) guidelines, insulin glargine products share the following characteristics:
- All insulin glargine formulations (including Lantus and YFGN) contain the same active ingredient at the same concentration 1
- They are designed to provide basal insulin coverage with a duration of action up to 24 hours 1
- They are typically administered once daily to regulate hepatic glucose production and limit hyperglycemia overnight and between meals 1
Clinical Equivalence
The ADA recognizes insulin glargine formulations as therapeutically equivalent in their pharmacokinetic properties:
- All insulin glargine products work by the same mechanism - precipitation in the neutral pH of subcutaneous tissue after injection, creating a depot that slowly releases insulin 2
- They all provide a relatively constant basal insulin level without pronounced peaks 3, 4
- The strength (100 units/mL) is standardized across insulin glargine products including Lantus and YFGN 1
Practical Implications
When switching between Lantus and insulin glargine YFGN:
- No dose adjustment is needed when transitioning between these products
- Both products can be administered once daily at the same dose
- Both are equally effective at controlling fasting blood glucose levels 3
- Both have similar safety profiles with comparable risks of hypoglycemia 2
Important Considerations
While the strength is identical, there are some practical points to remember:
- Always check the insulin concentration on the label (100 units/mL for both products)
- Never mix insulin glargine with other insulins in the same syringe as it may alter the time-action profile 5
- Both products should be stored according to manufacturer recommendations
- Insulin glargine products are not for intravenous use
Clinical Benefits of Insulin Glargine
Both Lantus and insulin glargine YFGN offer the same clinical advantages:
- Lower risk of nocturnal hypoglycemia compared to NPH insulin 3, 2
- Relatively constant basal insulin levels without pronounced peaks 4
- Once-daily dosing for most patients, though some may benefit from twice-daily administration 5
- Effective for both type 1 and type 2 diabetes management 3
In conclusion, patients can be reassured that insulin glargine YFGN and Lantus contain the same active ingredient at identical strength and can be used interchangeably without dose adjustment.